1.Sales and profit
See section β- MapLight Therapeutics, Inc. lost $161M in fiscal 2025.
MapLight Therapeutics, Inc.
MPLT Nasdaq Pharmaceutical Preparations Financials FY2024βFY2025
Last close Β· Oct 23, 2026
$7.97
3.4%KIRAβs summary AI analyst
Hi! I read MapLight Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
2 to watch
2.Cash and shareholders
See section β- Free cash flow was β$139M in fiscal 2025, β of revenue.
- In the last 12 months, insiders bought $175M and sold $30.2M of shares on the open market.
MapLight Therapeutics, Inc. in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β$161M
No. It lost money last year.
For information
How is the share priced?
0.2x
One share costs 0.2 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
$362M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
0.2x
On $47.22 EPS (TTM)
Charts by
Sales and profit
Is it selling more, and how much does it keep?
Revenue and margins
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
FY24
Revenue β
FY25
Revenue β
Margins, % of revenue
FY24
Gross β
Operating β
Net β
FCF β
FY25
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
Net income and earnings per share
KIRA Β· MapLight Therapeutics, Inc. lost $161M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
FY24
Net income β$77.6M
FY25
Net income β$161M
Net income
Q1 '24
Net income β$18.9M
Q2 '24
Net income β$18.4M
Q3 '24
Net income β$19.0M
Q4 '24
Net income β$21.2M
Q1 '25
Net income β$22.3M
Q2 '25
Net income β$29.8M
Q3 '25
Net income β$29.4M
Q4 '25
Net income β$79.5M
Q1 '26
Net income β$60.7M
Q2 '26
Net income β$60.2M
Diluted EPS
FY24
Diluted EPS β$105.38
FY25
Diluted EPS β$18.56
Diluted EPS
Q1 '24
Diluted EPS β
Q2 '24
Diluted EPS β
Q3 '24
Diluted EPS β$25.08
Q4 '24
Diluted EPS β
Q1 '25
Diluted EPS β$29.33
Q2 '25
Diluted EPS β$39.11
Q3 '25
Diluted EPS β$37.18
Q4 '25
Diluted EPS $87.06
Q1 '26
Diluted EPS β$1.34
Q2 '26
Diluted EPS β$1.32
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
KIRA Β· Free cash flow was β$139M in fiscal 2025, β of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
FY24
Free cash flow β$79.6M
FY25
Free cash flow β$139M
Free cash flow
Q1 '24
Free cash flow β
Q2 '24
Free cash flow β
Q3 '24
Free cash flow β
Q4 '24
Free cash flow β$21.6M
Q1 '25
Free cash flow β
Q2 '25
Free cash flow β
Q3 '25
Free cash flow β$31.8M
Q4 '25
Free cash flow β$47.2M
Q1 '26
Free cash flow β$51.2M
Q2 '26
Free cash flow β$44.9M
Cash from operations vs capital spending
FY24
Cash from operations β$78.8M
Capital spending $0.8M
FY25
Cash from operations β$138M
Capital spending $0.5M
Cash from operations
Capital spending
Cash from operations vs capital spending
Q1 '24
Cash from operations β
Capital spending β
Q2 '24
Cash from operations β
Capital spending β
Q3 '24
Cash from operations β
Capital spending β
Q4 '24
Cash from operations β$21.5M
Capital spending $0.1M
Q1 '25
Cash from operations β$25.6M
Capital spending β
Q2 '25
Cash from operations β$34.0M
Capital spending β
Q3 '25
Cash from operations β$31.8M
Capital spending $0.0M
Q4 '25
Cash from operations β$46.8M
Capital spending $0.4M
Q1 '26
Cash from operations β$51.2M
Capital spending $0.0M
Q2 '26
Cash from operations β$44.9M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY24
Diluted shares 0.00B
FY25
Diluted shares 0.01B
Insider trades
KIRA Β· In the last 12 months, insiders bought $175M and sold $30.2M of shares on the open market.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$175M
5 insiders
Sold, 12 months
$30.2M
8 insiders
Of sales under plans
66%
$20.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | James Woodruff LillieChief Scientific Officer | Sold | 11,513 | $8.08 | $0.1M | Form 4 |
| Oct 15, 2026 | Jonathan GillisCAO and Interim CFO | Sold | 10,167 | $8.08 | $0.1M | Form 4 |
| Oct 15, 2026 | Christopher A. KroegerChief Executive Officer, Director | Sold | 73,691 | $8.08 | $0.6M | Form 4 |
| Oct 15, 2026 | Erin Pennock FoffChief Medical Officer | Sold | 15,355 | $8.08 | $0.1M | Form 4 |
| Oct 15, 2026 | Anatol KreitzerChief Discovery Officer | Sold | 12,248 | $7.84 | $0.1M | Form 4 |
| Oct 15, 2026 | Kristopher HansonGeneral Counsel | Sold | 9,020 | $8.08 | $0.1M | Form 4 |
| Sep 16, 2026 | Kristopher HansonGeneral Counsel | Sold plan | 16,509 | $11.67 | $0.2M | Form 4 |
| Aug 14, 2026 | Catalyst4, Inc.10% owner | Bought | 4,400,000 | $11.38 | $50.1M | Form 4 |
| Aug 3, 2026 | James Woodruff LillieChief Scientific Officer | Sold plan | 22,082 | $12.54 | $0.3M | Form 4 |
| Jul 30, 2026 | Catalyst4, Inc.10% owner | Bought | 1,000,000 | $13.00 | $13.0M | Form 4 |
| Jul 29, 2026 | Catalyst4, Inc.10% owner | Bought | 3,000 | $12.63 | $0.0M | Form 4 |
| Jul 28, 2026 | Troy CoxDirector | Bought | 15,620 | $9.52 | $0.1M | Form 4 |
| Jul 28, 2026 | Catalyst4, Inc.10% owner | Bought | 206,225 | $11.04 | $2.3M | Form 4 |
| Jul 17, 2026 | Kristopher HansonGeneral Counsel | Sold | 1,130 | $37.90 | $0.0M | Form 4 |
| Jul 17, 2026 | James Woodruff LillieChief Scientific Officer | Sold | 2,077 | $37.90 | $0.1M | Form 4 |
| Jul 17, 2026 | Anatol KreitzerChief Discovery Officer | Sold plan | 17,173 | $37.60 | $0.6M | Form 4 |
| Jul 17, 2026 | Erin Pennock FoffChief Medical Officer | Sold plan | 3,656 | $37.90 | $0.1M | Form 4 |
| Jul 17, 2026 | Christopher A. KroegerChief Executive Officer, Director | Sold | 16,779 | $37.90 | $0.6M | Form 4 |
| Jul 17, 2026 | Jonathan GillisCAO and Interim CFO | Sold plan | 18,469 | $37.60 | $0.7M | Form 4 |
| Jul 16, 2026 | Kristopher HansonGeneral Counsel | Sold | 8,118 | $36.78 | $0.3M | Form 4 |
| Jul 16, 2026 | James Woodruff LillieChief Scientific Officer | Sold | 8,547 | $36.79 | $0.3M | Form 4 |
| Jul 16, 2026 | Erin Pennock FoffChief Medical Officer | Sold plan | 15,047 | $36.77 | $0.6M | Form 4 |
| Jul 16, 2026 | Christopher A. KroegerChief Executive Officer, Director | Sold | 69,082 | $36.79 | $2.5M | Form 4 |
| Jul 16, 2026 | Anatol KreitzerChief Discovery Officer | Sold plan | 9,056 | $36.80 | $0.3M | Form 4 |
| Jul 16, 2026 | Jonathan GillisCAO and Interim CFO | Sold plan | 8,455 | $36.80 | $0.3M | Form 4 |
| Jul 15, 2026 | Erin Pennock FoffChief Medical Officer | Sold plan | 28,455 | $36.64 | $1.0M | Form 4 |
| Jul 15, 2026 | James Woodruff LillieChief Scientific Officer | Sold | 7,643 | $36.70 | $0.3M | Form 4 |
| Jul 15, 2026 | Christopher A. KroegerChief Executive Officer, Director | Sold | 61,778 | $36.69 | $2.3M | Form 4 |
| Jul 15, 2026 | Jonathan GillisCAO and Interim CFO | Sold plan | 10,055 | $36.51 | $0.4M | Form 4 |
| Jul 15, 2026 | Kristopher HansonGeneral Counsel | Sold | 7,260 | $36.70 | $0.3M | Form 4 |
| Jul 15, 2026 | Anatol KreitzerChief Discovery Officer | Sold plan | 10,055 | $36.49 | $0.4M | Form 4 |
| May 18, 2026 | Christopher A. KroegerChief Executive Officer, Director | Sold plan | 118,235 | $27.19 | $3.2M | Form 4 |
| May 11, 2026 | Christopher A. KroegerChief Executive Officer, Director | Sold plan | 13,980 | $30.11 | $0.4M | Form 4 |
| May 11, 2026 | Kristopher HansonGeneral Counsel | Sold plan | 13,917 | $30.13 | $0.4M | Form 4 |
| May 8, 2026 | Christopher A. KroegerChief Executive Officer, Director | Sold plan | 34,411 | $27.69 | $1.0M | Form 4 |
| May 7, 2026 | Erin Pennock FoffChief Medical Officer | Sold plan | 4,438 | $28.54 | $0.1M | Form 4 |
| May 7, 2026 | Christopher A. KroegerChief Executive Officer, Director | Sold plan | 20,100 | $28.65 | $0.6M | Form 4 |
| May 7, 2026 | James Woodruff LillieChief Scientific Officer | Sold plan | 721 | $28.28 | $0.0M | Form 4 |
| May 6, 2026 | Vishwas SetiaChief Financial Officer | Sold plan | 10,564 | $28.24 | $0.3M | Form 4 |
| May 6, 2026 | James Woodruff LillieChief Scientific Officer | Sold plan | 24,811 | $28.76 | $0.7M | Form 4 |
| May 6, 2026 | Christopher A. KroegerChief Executive Officer, Director | Sold plan | 23,701 | $28.76 | $0.7M | Form 4 |
| May 6, 2026 | Erin Pennock FoffChief Medical Officer | Sold plan | 24,052 | $28.76 | $0.7M | Form 4 |
| May 5, 2026 | Christopher A. KroegerChief Executive Officer, Director | Sold plan | 10,472 | $28.20 | $0.3M | Form 4 |
| May 5, 2026 | James Woodruff LillieChief Scientific Officer | Sold plan | 11,095 | $28.20 | $0.3M | Form 4 |
| May 5, 2026 | Vishwas SetiaChief Financial Officer | Sold plan | 10,903 | $28.20 | $0.3M | Form 4 |
| May 5, 2026 | Erin Pennock FoffChief Medical Officer | Sold plan | 10,576 | $28.20 | $0.3M | Form 4 |
| May 4, 2026 | James Woodruff LillieChief Scientific Officer | Sold plan | 15,801 | $27.96 | $0.4M | Form 4 |
| May 4, 2026 | Christopher A. KroegerChief Executive Officer, Director | Sold plan | 15,571 | $27.96 | $0.4M | Form 4 |
| May 4, 2026 | Kristopher HansonGeneral Counsel | Sold plan | 13,917 | $27.89 | $0.4M | Form 4 |
| May 4, 2026 | Erin Pennock FoffChief Medical Officer | Sold plan | 15,652 | $27.96 | $0.4M | Form 4 |
| May 4, 2026 | Vishwas SetiaChief Financial Officer | Sold plan | 14,904 | $28.11 | $0.4M | Form 4 |
| Apr 28, 2026 | Jonathan GillisCAAO and PAO | Sold plan | 17,935 | $30.35 | $0.5M | Form 4 |
| Apr 27, 2026 | Jonathan GillisCAAO and PAO | Sold plan | 51,900 | $29.74 | $1.5M | Form 4 |
| Apr 27, 2026 | Anatol KreitzerChief Discovery Officer | Sold plan | 45,422 | $29.66 | $1.3M | Form 4 |
| Apr 16, 2026 | Erin Pennock FoffChief Medical Officer | Sold | 1,169 | $27.37 | $0.0M | Form 4 |
| Apr 16, 2026 | Kristopher HansonGeneral Counsel | Sold | 298 | $27.37 | $0.0M | Form 4 |
| Apr 16, 2026 | Vishwas SetiaChief Financial Officer | Sold | 116 | $27.37 | $0.0M | Form 4 |
| Apr 16, 2026 | James Woodruff LillieChief Scientific Officer | Sold | 2,783 | $27.37 | $0.1M | Form 4 |
| Apr 16, 2026 | Christopher A. KroegerChief Executive Officer, Director | Sold | 10,052 | $27.37 | $0.3M | Form 4 |
| Apr 15, 2026 | Vishwas SetiaChief Financial Officer | Sold | 2,806 | $26.87 | $0.1M | Form 4 |
| Apr 15, 2026 | Robert C. MalenkaDirector | Sold plan | 8,593 | $26.90 | $0.2M | Form 4 |
| Apr 15, 2026 | Anatol KreitzerChief Discovery Officer | Sold | 3,316 | $26.61 | $0.1M | Form 4 |
| Apr 15, 2026 | James Woodruff LillieChief Scientific Officer | Sold | 1,730 | $26.82 | $0.0M | Form 4 |
| Apr 15, 2026 | Jonathan GillisCAAO and PAO | Sold | 3,590 | $26.61 | $0.1M | Form 4 |
| Apr 15, 2026 | Erin Pennock FoffChief Medical Officer | Sold | 2,044 | $26.84 | $0.1M | Form 4 |
| Apr 15, 2026 | Kristopher HansonGeneral Counsel | Sold | 1,529 | $26.80 | $0.0M | Form 4 |
| Apr 15, 2026 | Christopher A. KroegerChief Executive Officer, Director | Sold | 9,135 | $26.93 | $0.2M | Form 4 |
| Feb 24, 2026 | Robert C. MalenkaDirector | Sold | 736 | $18.15 | $0.0M | Form 4 |
| Feb 23, 2026 | Robert C. MalenkaDirector | Sold | 11,264 | $18.42 | $0.2M | Form 4 |
| Feb 20, 2026 | Robert C. MalenkaDirector | Sold | 2,195 | $18.03 | $0.0M | Form 4 |
| Feb 20, 2026 | George PavlovDirector | Bought | 9,920 | $17.86 | $0.2M | Form 4 |
| Feb 19, 2026 | George PavlovDirector | Bought | 4,422 | $17.57 | $0.1M | Form 4 |
| Feb 18, 2026 | George PavlovDirector | Bought | 10,658 | $17.48 | $0.2M | Form 4 |
| Feb 13, 2026 | Robert C. MalenkaDirector | Sold | 12,116 | $18.21 | $0.2M | Form 4 |
| Feb 11, 2026 | Robert C. MalenkaDirector | Sold | 241 | $18.00 | $0.0M | Form 4 |
| Feb 10, 2026 | Robert C. MalenkaDirector | Sold | 6,622 | $18.12 | $0.1M | Form 4 |
| Feb 10, 2026 | Timothy John GarnettDirector | Bought | 14,124 | $17.89 | $0.3M | Form 4 |
| Feb 3, 2026 | Robert C. MalenkaDirector | Sold | 1 | $18.00 | $0.0M | Form 4 |
| Feb 2, 2026 | Robert C. MalenkaDirector | Sold | 7,039 | $18.02 | $0.1M | Form 4 |
| Jan 30, 2026 | Robert C. MalenkaDirector | Sold | 6,612 | $18.11 | $0.1M | Form 4 |
| Jan 29, 2026 | Robert C. MalenkaDirector | Sold | 21,262 | $18.55 | $0.4M | Form 4 |
| Jan 28, 2026 | Robert C. MalenkaDirector | Sold | 6,524 | $18.65 | $0.1M | Form 4 |
| Oct 28, 2025 | Novo Holdings A/S10% owner | Bought | 952,941 | $17.00 | $16.2M | Form 4 |
| Oct 28, 2025 | Catalyst4, Inc.10% owner | Bought | 5,441,176 | $17.00 | $92.5M | Form 4 |
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably MapLight Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
FY24
Cash $109M
Debt β
FY25
Cash $305M
Debt β
Cash
Debt
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $109M | $305M |
| Current ratio | 7.2x | 20.0x |
| Quick ratio | 7.2x | 20.0x |
| Total assets | $137M | $480M |
| Total liabilities | $21.7M | $21.1M |
| Shareholders' equity | β$194M | $458M |
| Net debt (β = net cash) | β | β |
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
FY24
Return on capital β
Return on equity β
Return on assets β56.7%
FY25
Return on capital β
Return on equity β121.7%
Return on assets β52.3%
Return on capital
Return on equity
Return on assets
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | β | β |
| Cash from operations is positive | β | β |
| Return on assets rose | β | β |
| Cash from operations exceeds net income | β | β |
| Debt fell relative to assets | β | β |
| Current ratio rose | β | β |
| Share count didn't rise | β | β |
| Gross margin rose | β | β |
| Revenue rose relative to assets | β | β |
| F-score | β / 3 | β / 6 |
| Accruals ratio | 0.9% | β7.5% |
| Altman Z'' | β13.45 | 22.17 |
All figures
Every number, year by year.
2 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Research and development | $68.5M | $138M |
| Operating income | β$82.9M | β$169M |
| Net income | β$77.6M | β$161M |
| Diluted EPS | β$105.38 | β$18.56 |
| Diluted shares | 0.00B | 0.01B |
| Cash flow | ||
| Cash from operations | β$78.8M | β$138M |
| Capital expenditure | $0.8M | $0.5M |
| Free cash flow | β$79.6M | β$139M |
| Depreciation and amortization | $0.7M | $0.6M |
| Stock-based compensation | $1.1M | $36.0M |
| Balance sheet | ||
| Cash and short-term investments | $109M | $305M |
| Current assets | $115M | $325M |
| Current liabilities | $15.9M | $16.2M |
| Property and equipment, net | $1.2M | $1.1M |
| Total assets | $137M | $480M |
| Total liabilities | $21.7M | $21.1M |
| Shareholders' equity | β$194M | $458M |
| Returns | ||
| Return on capital employed | β68.6% | β36.5% |
| Return on equity | β | β121.7% |
| Return on assets | β56.7% | β52.3% |
| Return on tangible equity | β | β35.2% |
| Growth | ||
| Share count change | β | 1,079.1% |
| Financial health | ||
| Current ratio | 7.2x | 20.0x |
| Quick ratio | 7.2x | 20.0x |
| Quality scores | ||
| Altman Z'' | β13.5 | 22.2 |
| Accruals ratio | 0.9% | β7.5% |
Source: SEC EDGAR XBRL filings (CIK 0001770069). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.